Molecular Partners Ag (MOLN) EBITDA (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly EBITDA of -$16799.0 for Q1 2026, up 15.64% year-over-year from -$14526.8 in Q1 2025, and up 99.98% quarter-over-quarter from -$75.5 million in Q4 2025.
Molecular Partners Ag (MOLN) EBITDA (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported EBITDA for 7 consecutive years, with -$16799.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA rose 15.64% year-over-year to -$16799.0; the TTM figure through Mar 2026 stood at -$96.5 million (down 20.79% YoY), while the FY2025 annual figure was -$72.7 million, down 4.07% from the prior year.
- EBITDA climbed to -$16799.0 in Q1 2026 per MOLN's latest filing, from -$75.5 million in the prior quarter.
- Across five years, EBITDA topped out at $158.4 million in Q2 2022 and bottomed at -$75.5 million in Q4 2025.
- Historically, EBITDA has averaged $1.6 million across 5 years, with a median of -$16799.0 in 2026.
- Annual changes were most pronounced in 2022 — EBITDA soared 1016.85% — and 2023, when it plunged 151.61%.
- Molecular Partners Ag's EBITDA stood at $128.4 million in 2022, then slumped by 151.61% to -$66.3 million in 2023, then climbed by 6.19% to -$62.2 million in 2024, then declined by 21.49% to -$75.5 million in 2025, then surged by 99.98% to -$16799.0 in 2026.
- Business Quant data shows MOLN's EBITDA at -$16799.0 in Q1 2026, -$75.5 million in Q4 2025, and -$14992.6 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.96 Bn | 132.11 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.79 Bn | 78.79 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 60.20 Bn | 55.06 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.19 Bn | 37.09 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.43 Bn | 28.12 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.65 Bn | 10.26 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 133.12 Mn |
| 10 | Molecular Partners Ag | 163.25 Mn | 163.25 Mn | - | -17,166.77 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,799.00 |
| Dec 31, 2025 | -75.53 Mn |
| Sep 30, 2025 | -14,992.56 |
| Jun 30, 2025 | -20.92 Mn |
| Mar 31, 2025 | -19,913.73 |
| Dec 31, 2024 | -62.16 Mn |
| Sep 30, 2024 | -21,857.22 |
| Jun 30, 2024 | -17.67 Mn |
| Mar 31, 2024 | -12,986.31 |
| Dec 31, 2023 | -66.26 Mn |
| Sep 30, 2023 | -12,963.15 |
| Jun 30, 2023 | -17.66 Mn |
| Mar 31, 2023 | -16,579.63 |
| Dec 31, 2022 | 128.38 Mn |
| Sep 30, 2022 | -13,915.50 |
| Jun 30, 2022 | 158.39 Mn |
| Mar 31, 2022 | 166,076.82 |
| Dec 31, 2021 | -68.49 Mn |
| Sep 30, 2021 | -13,548.77 |
| Jun 30, 2021 | -37.14 Mn |